Human immunoglobulin for intravenous injection (IVIG) has the capacity of proving passive immunity and anti-inflammatory, immunomodulatory effect which results in better treatment and prognosis of severe infections such as COVID-19. The IgG antibodies extracted from recovered patients of COVID-19 are expected to boost the immune response in newly infected patients, leading to a reduction in the treatment duration. Hence, the combination of the immune IgG antibodies as human immunoglobulin for intravenous injection (IVIG) with antiviral drugs can offer short-term and medium-term solutions against COVID-19. Hence, the COVID-19 outbreak is expected to increase demand for human immunoglobulin (pH4) for intravenous injection which is expected to boost the growth of global human immunoglobulin (Ph4) for intravenous injection market.
Market Dynamics
The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to enhance their market presence is expected to propel the market growth during the forecast period. For instance, in January 2020, ADMA Biologics, Inc., a manufacturer, and distributor of plasma-derived biologics, entered a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA’s Immune Globulin (IG) manufacturing process. Under this agreement, ADMA Biologics, Inc. will maximize the revenue per liter of plasma fractionated in its plant by selling the fractioned plasma to a third party to develop their therapeutic products under their own licensed manufacturing processes.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook